News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ARCA biopharma Release: Gencaro™ Potential Efficacy in Preventing Atrial Fibrillation Paper Published in JACC: Heart Failure


6/6/2013 10:12:01 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

BROOMFIELD, Colo.--(BUSINESS WIRE)--ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that the paper “Prevention of Atrial Fibrillation by Bucindolol is Dependent on the Beta-1 389 Arg/Gly Adrenergic Receptor Polymorphism” was published in the journal JACC: Heart Failure [http://heartfailure.onlinejacc.org/article.aspx?articleid=1691088], a publication of the American College of Cardiology. The lead author on the paper is cardiologist-electrophysiologist Ryan G. Aleong of the University of Colorado, Anschutz Medical Campus and the senior author on the paper is Dr. Michael Bristow, the Company’s Chief Executive Officer.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES